A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma

Uterine serous carcinoma (USC) is an uncommon subtype of endometrial cancer with a poor prognosis. USCs have genomic alterations in the PI3K pathway. A prior phase II study of AKT inhibitor MK-2206 (an allosteric AKT inhibitor, primarily affecting AKT1 and AKT2) in endometrial cancers resulted in pr...

Full description

Bibliographic Details
Main Authors:	Elizabeth H. Stover, Niya Xiong, Andrea P. Myers, Nabihah Tayob, Victoria Engvold, Madeline Polak, Russell R. Broaddus, Vicky Makker, Ronny Drapkin, Joyce F. Liu, Neil S. Horowitz, Funda Meric-Bernstam, Carol Aghajanian, Robert L. Coleman, Gordon B. Mills, Lewis C. Cantley, Ursula A. Matulonis, Shannon N. Westin, Panagiotis A. Konstantinopoulos
Format:	Article
Language:	English
Published:	Elsevier 2022-04-01
Series:	Gynecologic Oncology Reports
Subjects:	Uterine serous carcinoma MK-2206 AKT inhibitor PI3K/AKT pathway
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352578922000546

Internet

http://www.sciencedirect.com/science/article/pii/S2352578922000546

A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma

Internet

Similar Items